IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression.
暂无分享,去创建一个
Guanqun Li | Hua Chen | Le Li | Qi Liu | Ze Yu | Q. Lang | Tiemin Pei | Zhijie Yin | Yilin Xu | Qinghui Meng | Peng Xiao | Liwei Liu | Zhibo Li | Yangyang Zhang | Bei Sun | Yu Xie | Qi Geng
[1] Yan He,et al. Blockade of Nuclear β‐Catenin Signaling via Direct Targeting of RanBP3 with NU2058 Induces Cell Senescence to Suppress Colorectal Tumorigenesis , 2022, Advanced science.
[2] Jakob Nikolas Kather,et al. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions , 2022, Gut.
[3] Huadong Liu,et al. Prostate-specific oncogene OTUD6A promotes prostatic tumorigenesis via deubiquitinating and stabilizing c-Myc , 2022, Cell Death & Differentiation.
[4] Wei Zhao,et al. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner , 2022, Oncogene.
[5] Arnaud J. Legrand,et al. The NUCKS1-SKP2-p21/p27 axis controls S phase entry , 2021, Nature Communications.
[6] Xuejun Sun,et al. Multilevel regulation of Wnt signaling by Zic2 in colon cancer due to mutation of β-catenin , 2021, Cell Death & Disease.
[7] Cuiping Yang,et al. The role of m6A modification in the biological functions and diseases , 2021, Signal Transduction and Targeted Therapy.
[8] L. Qi,et al. Zic Family Member 2 (ZIC2): a Potential Diagnostic and Prognostic Biomarker for Pan-Cancer , 2021, Frontiers in Molecular Biosciences.
[9] Alice Wedler,et al. The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer , 2020, Nucleic acids research.
[10] De Chen,et al. An oncopeptide regulates m6A recognition by the m6A reader IGF2BP1 and tumorigenesis , 2020, Nature Communications.
[11] J. Ferlay,et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012 , 2020, Cancer.
[12] Ming Zhao,et al. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. , 2019, Journal of hepatology.
[13] Jianren Gu,et al. A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA. , 2019, Cancer letters.
[14] A. Alimonti,et al. Cellular Senescence: Aging, Cancer, and Injury. , 2019, Physiological reviews.
[15] Gang Wu,et al. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway , 2019, Journal of experimental & clinical cancer research : CR.
[16] Jianjun Chen,et al. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner , 2018, Nucleic acids research.
[17] A. Minden,et al. P21 activated kinase signaling in cancer. , 2019, Seminars in cancer biology.
[18] Karen E Gascoigne,et al. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. , 2018, Cell reports.
[19] R. Flavell,et al. RNA m6A modification and its function in diseases , 2018, Frontiers of Medicine.
[20] Hong Zhang,et al. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer , 2018, Journal of Hematology & Oncology.
[21] Stefan Hüttelmaier,et al. Recognition of RNA N6-methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation , 2018, Nature Cell Biology.
[22] Samie R Jaffrey,et al. Rethinking m6A Readers, Writers, and Erasers. , 2017, Annual review of cell and developmental biology.
[23] C. Mao,et al. A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation , 2017, Translational oncology.
[24] J. Yun,et al. Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma. , 2017, Cancer letters.
[25] Chuan He,et al. Post-transcriptional gene regulation by mRNA modifications , 2016, Nature Reviews Molecular Cell Biology.
[26] P. Zhu,et al. ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. , 2015, The Journal of clinical investigation.
[27] D. Altshuler,et al. IGF2BP2/IMP2-Deficient mice resist obesity through enhanced translation of Ucp1 mRNA and Other mRNAs encoding mitochondrial proteins. , 2015, Cell metabolism.
[28] B. Njei. Changing pattern of epidemiology in intrahepatic cholangiocarcinoma , 2014, Hepatology.
[29] P. Schirmacher,et al. Insulin‐like growth factor 2 mRNA‐binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma , 2014, Hepatology.
[30] Samie R. Jaffrey,et al. The dynamic epitranscriptome: N6-methyladenosine and gene expression control , 2014, Nature Reviews Molecular Cell Biology.
[31] I Celardo,et al. Senescence and aging: the critical roles of p53 , 2013, Oncogene.
[32] Sae-Ock Oh,et al. WTAP regulates migration and invasion of cholangiocarcinoma cells , 2013, Journal of Gastroenterology.
[33] M. Lederer,et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? , 2012, Cellular and Molecular Life Sciences.
[34] Q. Zhan,et al. BAG2 is a target of the c-Myc gene and is involved in cellular senescence via the p21(CIP1) pathway. , 2012, Cancer letters.
[35] K. Yao,et al. Zic2 synergistically enhances Hedgehog signalling through nuclear retention of Gli1 in cervical cancer cells , 2011, The Journal of pathology.
[36] W. Hahn,et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. , 2008, Cancer cell.
[37] Dean W. Felsher,et al. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation , 2007, Proceedings of the National Academy of Sciences.